Everything biobased: plastic, medicine, and fuel. It seems like a futuristic utopia. But for how long? A collaboration of researchers now proposes an idea to accelerate the development process. By ...

IBB is iShares Nasdaq Biotechnology ETF tracking Nasdaq Biotechnology Index. In the last three years, IBB has remained flat and significantly underperformed the S&P 500. For retail investors, we think ...

In 2025, fewer biotech deals are getting done, but the dollars behind them are bigger than ever. Having spent years working with emerging and fast-growth life sciences companies, I’ve seen firsthand ...

In the past six months, there have been 33 biotech acquisitions valued at $1 billion or more, capped by AbbVie’s acquisition ...

The world of biotech stocks offers a unique blend of high risk and potentially high reward. Companies operating in this space are constantly pushing the boundaries, making them primed investment ...

Mr. Dreyer is an American editor and writer who lives in Shanghai. See more of our coverage in your search results.Encuentra más de nuestra cobertura en los resultados de búsqueda. Add The New York ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...